Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience

Mellstedt, Håkan; Vansteenkiste, Johan; Thatcher, Nick

doi:10.1016/j.lungcan.2011.02.023

Cited by 49 publications

(36 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The human tumor antigen MAGE-A3, of the cancer/testis antigen group (13), is frequently expressed in lung cancers (14) and a MAGE-A3-based anticancer vaccine is currently being evaluated in lung cancer patients (15). We assessed circulating lymphocytes from 38 lung cancer patients (Supplementary Table S2) for spontaneous CD4 þ T-cell responses to MAGE-A3.…”

Section: Resultsmentioning

confidence: 99%

Human TH17 Immune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN-γ–Secreting Cells as They Differentiate into Effector T Cells In Vivo

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Human TH17 Immune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN-γ–Secreting Cells as They Differentiate into Effector T Cells In Vivo

et al. 2012

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5] In the last 15 years, several attempts have been made to combine different therapeutic modalities with ASI in the treatment of solid malignancies in order to improve its antitumor efficacy. Radio-and chemoimmunotherapy have produced promising results in both preclinical and clinical studies.…”

Section: Introductionmentioning

confidence: 99%

Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients

et al. 2016

View full text Add to dashboard Cite

“…The subsequent therapeutic target involves receptor for epithelial growth factor (EGFR) commonly present on cells of lung cancer [77]. Its activity can be inhibited using CIMAvax vaccine, taking advantage of the antibody specific for EGFR [89]. Until now, few recognised epitopes of cancer cells were described [121], such as, for example, peptides in patients with melanoma [21,46] and in ovarian cancer [114].…”

Section: Markers Of Neoplastic Cells On the Example Of Lung Cancermentioning

confidence: 99%

“…Their very early stages remain unknown but considering behaviour of cells in one of leukaemias (chronic B-cell laukaemia) [90,146], certain hypotheses can be suggested. Normal B lymphocytes of CD19 + CD5 + subpopulation continuously produce antibodies and in that function require no activation by T lymphocytes.…”

Section: Development Of Systemic Tumours On the Example Of B-lymphocymentioning

confidence: 99%

Problems of Cancer Treatment. Part I. Theory of Treatment Based on Known Mechanisms of Anticancer Immunological Responses

Kawiak

Hoser

Domagała‐Kulawik

2017

Advances in Cell Biology

View full text Add to dashboard Cite

Summary: Various processes, taking place both in cells and in their environment, are linked to carcinogenesis. This paper aims at recalling the complex mechanisms of oncogenesis, with particular attention paid to responses of the immune system. In development of solid tumours, leukaemias and lymphomas several common stages can be noted. A neoplastic disease cannot be understood considering only phenomena of genetic mutations. Neoplastic cells are characterised by an extensive antigenic variability and resistance to apoptosis. The cells create around them a microenvironment which protects them from defensive activity of the host. In the paper we present the recognised mechanisms of anti-neoplastic defense as well as several elements allowing the solid tumours and leukaemias to escape from the immune surveillance. The generally accepted treatment of tumours aims at reducing numbers of tumour cells. Following resection of a tumour, radiotherapy or chemotherapy, the parallel or consecutive stage of treatment was found to involve an increase in number of clones of immune system cells. One of the ways in which the immune system can be activated involves autovaccination of the host with own neoplastic cells in an apoptosis. However, attempts of such a therapy frequently brought no expected results due to blocked activity of cytotoxic cells. Therefore, the subsequent stage in activation of the immune system should involve elimination of the tumor-mobilized blockade of the system. Attempts toward this aim include neutralization of the tumour-blocked cytotoxic properties of defensive cells, first of all T lymphocytes. The recognized mechanisms of blocking T cells activity in the PD-1/PD-L1 system or due to inhibition of activation by CTLA-4 molecule provided rationale for development of effective tumour immunotherapy approaches. Keywords

show abstract

Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience

Cited by 49 publications

References 77 publications

Human TH17 Immune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN-γ–Secreting Cells as They Differentiate into Effector T Cells In Vivo

Human TH17 Immune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN-γ–Secreting Cells as They Differentiate into Effector T Cells In Vivo

Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients

Problems of Cancer Treatment. Part I. Theory of Treatment Based on Known Mechanisms of Anticancer Immunological Responses

Contact Info

Product

Resources

About